![]() (2023) Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner. I collaborate with biochemists and geneticists who use additional procedures such as metabolomics and DNA methylation analyses to further help our understanding of the mechanisms mediating a drug’s or a neurological disease’s effects for the development of medications.Įlder HJ, Varshneya NB, Walentiny DM, Beardsley PM. For developing medications for other neurological disorders, I have used a variety of behavioral pharmacological procedures, including Pavlovian-conditioned fear, startle and locomotor activity procedures. These models include physical dependence, self-administration and drug-discrimination procedures that model the withdrawal effects of drugs, their rewarding and subjective effects, respectively. For drug abuse related projects I have used procedures that closely parallel human experimental procedures or clinical phenomena. I have sought leads to the answers to these questions by using a variety of laboratory animal models. In particular, I am interested in answering questions about the nature of the controlling determinants involved in drug abuse and the development of medications for treating drug abuse and other neurological disorders such as post-traumatic stress disorder, depression and psychosis. ![]() My research interests involve these questions of behavioral pharmacology. The identification of these controlling factors and their interrelationships with the direct pharmacological actions of drugs is the domain of the science of behavioral pharmacology. The way in which a drug can control or modify behavior is dependent upon several factors. Medication development for CNS disorders.Behavioral pharmacology of drugs of abuse.Department: Department of Pharmacology and ToxicologyĮmail: Robert Blackwell Smith Building, Room 756B
0 Comments
Leave a Reply. |